Serum thrombopoietin and interleukin 6 concentrations in tumour patients and response to chemotherapy-induced thrombocytopenia

European Journal of Haematology

Volumn 59, Issue 1, 1997, Pages 53-58

  Heits, F ^a   Katschinski, D M ^a   Wilmsen, U ^a   Wiedemann, G J ^a   Jelkmann, W ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Chemotherapy; Megakaryocyte growth and development factor; MPL ligand; Thrombocytes; Thrombopoietin; Tumour patients

Indexed keywords

CARBOPLATIN; ETOPOSIDE; IFOSFAMIDE; INTERLEUKIN 11; INTERLEUKIN 6; THROMBOPOIETIN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER; CANCER CHEMOTHERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0030750435     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1997.tb00959.x     Document Type: Article

References (30)

1. NEWLAND AC. The problem of thrombocytopenia and its management. Anti-Cancer Drugs 1995: 6: 65-73.
2. AVRAHAM H. Regulation of megakaryocytopoiesis. Stem Cells 1993: 11: 499-510.
3. GORDON MS, HOFFMAN R. Growth factors affecting human thrombocytopoiesis: potential agents for the treatment of thrombocytopenia. Blood 1992: 80: 302-307.
4. KAUSHANSKY K. Thrombopoietin: the primary regulator of platelet production. Blood 1995: 86: 419-431.
5. VIGON I, MORNON J-P, COCAULT L, et al. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci USA 1992: 89: 5640-5644.
6. LOK S, KAUSHANSKY K, HOLLY RD, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994: 369: 565-568.
7. DE SAUVAGE FJ, HASS PE, SPENCER SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994: 369: 533-538.
8. BARTLEY TD, BOGENBERGER J, HUNT P, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994: 77: 1117-1124.
9. WENDLING F, MARASKOVSKY E, DEBILL N, et al. c-Mpl ligand is a humoral regulator of megakaryocytopoiesis. Nature 1994: 369: 571-574.
10. WIEDEMANN GJ, ROBINS HI, GUTSCHE S, et al. Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8°C whole-body hyperthermia in patients with refractory sarcoma. Eur J Cancer 1996: 324: 888-892.
11. MARSH JCW, GIBSON FM, PRUE RL, et al. Serum thrombopoietin levels in patients with aplastic anaemia. Br J Haematol 1996: 95: 605-610.
12. TAHARA T, USUKI K, SATO H, et al. A sensitive sandwich ELISA for measuring thrombopoietin in human serum: serum thrombopoietin levels in healthy volunteers and in patients with haemopoietic disorders. Br J Haematol 1996: 93: 783-788.
13. ESTROV Z, TALPAZ M, MAVLIGIT G, et al. Elevated plasma thrombopoietic activity in patients with metastatic cancer-related thrombocytosis. Am J Med 1995: 98: 551-558.
14. WILLIAMS N. Is thrombopoietin interleukin 6? Exp Hematol 1991: 19: 714-718.
15. STRANEVA JE, VAN BESIEN KW, DERIGS G, HOFFMAN R. Is interleukin 6 the physiological regulator of thrombopoiesis? Exp Hematol 1992: 20: 47-50.
16. GASTL, G, PLANTE M, FINSTAD CL, et al. High IL-6 levels in ascitic fluid correlate wih reactive thrombocytosis in patients with epithelial ovarian cancer. Br J Haematol 1993: 83: 433-441.
17. BLAY J-Y, FAYROT M, ROSSI J-F, WIJDENEX J. Role of interleukin-6 in paraneoplastic thrombocytosis. Blood 1993: 82: 2261-2262.
18. BRUNO E, BRIDDELL RA, COOPER RJ, HOFMANN R. Effects of recombinant interleukin 11 on human megakaryocyte progenitor cells. Exp Hematol 1991: 19: 378-381.
19. BROUDY VC, LIN NL, KAUSCHANSKY K. Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood 1995: 85: 1719-1726.
20. NICHOL JL, HOKOM MM, HORNKOHL A, et al. Megakaryocyte growth and development factor. J Clin Invest 1995: 95: 2973-2978.
21. MENG YG, MARTIN TG, PETERSON ML, SHUMAN MA, COHEN RL, WONG WL. Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation. Br J Haematol 1996: 95: 535-541.
22. MCDONALD TP. Thrombopoietin. Its biology, purification, and characterization. Exp Hematol 1988: 16: 201-205.
23. KUTER DJ, ROSENBERG RD. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 1995: 85: 2720-2730.
24. FIELDER PJ, GURNEY AL, STEFANICH E, et al. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 1996: 87: 2154-2161.
25. DE SAUVAGE FJ, CARVER-MOORE K, LUOH S-M, et al. Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med 1996: 183: 651-656.
26. STOFFEL R, WIESTNER A, SKODA RC. Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood 1996: 87: 567-573.
27. SUNGARAN R, MARKOVIC B, CHONG BH. Localization and regulation of thrombopoietin mRNA expression in human kidney, liver, bone marrow, and spleen using in situ hybridization. Blood 89: 1997: 101-107.
28. BASSER RL, RASKO JEJ, CLARKE K, et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 1996: 348: 1279-1281.
29. O'MALLEY CJ, RASKO JEJ, BASSER RL, et al. Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation. Blood 1996: 88: 3288-3298.
30. FANUCCHI M, GLASPY J, CRAWFORD J, et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997: 336: 404-409.